ArticleJournal of neuro-oncology2013
Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates.
Article in Journal of neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- A Comparison of PET Tracers in Recurrent High-Grade Gliomas: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Diagnostic Performance and Prognostic Value of PET/CT with Different Tracers for Brain Tumors: A Systematic Review of Published Meta-Analyses.International journal of molecular sciences · 2019Pooled it
- Evaluating "brain permeability": A critical issue for the development of therapeutic agents for primary and metastatic brain tumors.Neuro-oncology · 2026Review
- Unique Peritumoral Patterns Unveiled by Quantitative Multiparametric MRI and Their Diagnostic and Prognostic Value in Treated Malignant Gliomas.NMR in biomedicine · 2026Article
- Cutting-edge approaches in pet imaging for gliomas: current applications for neurooncologists and the path to theranostic breakthroughs.European journal of nuclear medicine and molecular imaging · 2026Review
- Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology-From Bench to Bedside.Biomolecules · 2025Review
- Diagnostic and theranostic opportunities in Neuro-oncology.Advances in oncology · 2024Article
- Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO group.Neuro-oncology · 2022Article
- Multimodal neuroimaging of gliomatosis cerebri: a case series of four patients.Acta radiologica open · 2020Article
- Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival.Neuro-oncology · 2019Article
- Feasibility of Multimodal MRI-Based Deep Learning Prediction of High Amino Acid Uptake Regions and Survival in Patients With Glioblastoma.Frontiers in neurology · 2019Article
- Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.Clinical nuclear medicine · 2017Article
- Optical-sectioning microscopy of protoporphyrin IX fluorescence in human gliomas: standardization and quantitative comparison with histology.Journal of biomedical optics · 2017Article
- MR Fingerprinting of Adult Brain Tumors: Initial Experience.AJNR. American journal of neuroradiology · 2017Article
- The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy.NeuroImage. Clinical · 2017Review
- Tryptophan PET predicts spatial and temporal patterns of post-treatment glioblastoma progression detected by contrast-enhanced MRI.Journal of neuro-oncology · 2016Article
- Imaging cerebral tryptophan metabolism in brain tumor-associated depression.EJNMMI research · 2015Article
- Multi-modal imaging of tumor cellularity and Tryptophan metabolism in human Gliomas.Cancer imaging : the official publication of the International Cancer Imaging Society · 2015Article
- Increased tryptophan uptake on PET has strong independent prognostic value in patients with a previously treated high-grade glioma.Neuro-oncology · 2014Article
- Clinical significance of tryptophan metabolism in the nontumoral hemisphere in patients with malignant glioma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Pretreatment delineation of infiltrating glioma volume remains suboptimal with current neuroimaging techniques. Gadolinium-enhanced T1-weighted (T1-Gad) MR images often underestimate the true extent of the tumor, while T2-weighted images preferentially highlight peritumoral edema. Accumulation of α-[(11)C]methyl-L-tryptophan (AMT) on positron emission tomography (PET) has been shown in gliomas. To determine whether increased uptake on AMT-PET would detect tumor-infiltrated brain tissue outside the contrast-enhancing region and differentiate it from peritumoral vasogenic edema, volumes and spatial concordance of T1-Gad and T2 MRI abnormalities as well as AMT-PET abnormalities were analyzed in 28 patients with newly-diagnosed WHO grade II-IV gliomas. AMT-accumulating grade I meningiomas were used to define an AMT uptake cutoff threshold that detects the tumor but excludes peri-meningioma vasogenic edema. Tumor infiltration in AMT-accumulating areas was studied in stereotactically-resected specimens from patients with glioblastoma. In the 28 gliomas, mean AMT-PET-defined tumor volumes were greater than the contrast-enhancing volume, but smaller than T2 abnormalities. Volume of AMT-accumulating tissue outside MRI abnormalities increased with higher tumor proliferative index and was the largest in glioblastomas. Tumor infiltration was confirmed by histopathology from AMT-positive regions outside contrast-enhancing glioblastoma mass, while no or minimal tumor cells were found in AMT-negative specimens. These results demonstrate that increased AMT accumulation on PET detects glioma-infiltrated brain tissue extending beyond the contrast-enhanced tumor mass. While tryptophan uptake is low in peritumoral vasogenic edema, AMT-PET can detect tumor-infiltrated brain outside T2-lesions. Thus, AMT-PET may assist pretreatment delineation of tumor infiltration, particularly in high-grade gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.